Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides

A technology of antibodies and compounds, applied in the direction of anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, peptide, specific peptide, etc., can solve the problem of limiting the usefulness of imaging agents

Inactive Publication Date: 2015-05-13
AMBRX
View PDF84 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this antibody recognizes intracellular epitopes of PSMA, which limits its usefulness as an imaging agent for the detection of PSMA

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
  • Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
  • Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides

Examples

Experimental program
Comparison scheme
Effect test

example 1

[1347] Example 1: Synthesis of Compound 1

[1348] 1. Displayed in Figure 8 The detailed synthesis of compound 1 in

[1349] 1a. Synthesis of Compounds 1-3

[1350] Add dexamethasone 1-1 (0.4 g, 1.02 mmol) and N,N'-disuccinimidyl carbonate (0.4 g, 1.33 mmol) in DCM (4 ml) and THF (4 ml) at room temperature DIEA (0.36ml, 2.04mmol) was added to the mixture. The mixture was stirred overnight at room temperature. The mixture was concentrated and the crude product was purified by column chromatography. Obtained 0.13 g of 1-3 (24%) as a white solid. LCMS m / z=534[M+H]+

[1351] 1b. Synthesis of Compound 1-7

[1352] To a mixture of 1-4 (0.3g, 0.6mmol), 1-5 (0.12g, 0.66mmol) and EDC (0.2g, 1.2mmol) in DMF (6ml) was added 1N NaHCO3 (1.8mmol) at 0°C ) solution. The mixture was stirred overnight at room temperature. The mixture was extracted with EtOAc (3 x 30ml), and the mixture was washed with 0.5M HCl and brine. The organic layer was dried with anhydrous MgSO4. The organi...

example 2

[1359] Example 2: Synthesis of Compound 2

[1360] 2. Shown in Figure 9 The detailed synthesis of compound 2 in

[1361] 2a. Synthesis of Compound 2-2

[1362] To a mixture of 1-3 (0.1 g, 0.19 mmol) and tert-butyl 2-aminoethylcarbamate (30 g, 0.19 mmol) in acetonitrile (2 ml) was added DIEA (0.098 ml, 0.56 mmol) at room temperature. The mixture was stirred overnight at room temperature. The white precipitate was filtered and washed with diethyl ether to give the product 2-1 as a white solid.

[1363] A mixture of 2-1 (0.1 g) and 4N HCl in dioxane (1 ml) was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure to give product 2-2 as a white solid. The product was used without further purification. LCMS m / z=479[M+H]+

[1364] 2b. Synthesis of Compound 2-4

[1365] To a mixture of 2-2 (0.09 g, 0.188 mmol) and Fmoc-Val-Cit-PAB-PNP (0.159 g, 0.21 mmol) in DMF (1 ml) was added DIEA (0.16 ml, 0.94 mmol) at room temperature. The mixture...

example 3

[1372] Example 3: Synthesis of Compound 3

[1373] 3. Shown in Figure 10 The detailed synthesis of compound 3 in.

[1374] 3a. Synthesis of Compound 3-1

[1375] To a solution of compound 3 (600 mg, 1.125 mmol) in 0.5 mL DMF was added tert-butyl methyl(2-(methylamino)ethyl)carbamate (127 mg, 0.675 mmol). The resulting solution was stirred at room temperature for 2 hours. The reaction mixture was diluted with EtOAc and washed with H2O, brine, dried over Na2SO4, then concentrated to dryness. The residue was purified by flash column chromatography to obtain 170 mg of compound 3-1. MS(ESI) m / z 607[M+H].

[1376] 3b. Synthesis of compound 3-2

[1377] Compound 3-1 (170 mg) was treated with 50% TFA in DCM. The reaction was concentrated to dry after 30 min. The product was used directly in the next step without further purification.

[1378] 3c. Synthesis of compound 3-3

[1379] Add Fmoc-Val-Cit-PAB-OPNP (215 mg, 0.28 mmol), HOBt (21.4 mg, 0.14 mmol) and DIEA (99 μl, 0.56...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

This invention relates to anti-prostate-specific membrane antigen antibodies (alphaPSMA) and alphaPSMA antibody - nuclear receptor ligand (NRL) conjugates comprising at least one non-naturally-encoded amino acid.

Description

technical field [0001] The present invention relates to anti-prostate specific membrane antigen antibodies (αPSMA) and αPSMA antibody-nuclear receptor ligand (NRL) conjugates comprising at least one non-naturally encoded amino acid. Background technique [0002] Prostate cancer is the most commonly diagnosed non-skin-related malignancy in men in developed countries. It is estimated that one in six men will be diagnosed with prostate cancer. The diagnosis of prostate cancer has been greatly improved with the use of serum-based markers such as prostate-specific antigen (PSA). In addition, prostate tumor-associated antigens provide targets for tumor imaging, diagnosis, and targeted therapy. Prostate-specific membrane antigen (PSMA), a prostate tumor-associated marker, is such a target. [0003] PSMA is a glycoprotein that is highly restricted to the membrane of secretory epithelial cells of the prostate. Its expression level has been correlated with tumor aggressiveness. V...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/48C07K16/30
CPCC07K16/3069A61K47/6869C07K16/3076
Inventor 孙英邹宁雅玛·希威特杰森·K.·平克斯塔夫纱伊拉加·旭瑞贾许理查德·S.·巴奈特芬·蒂昂安娜-玛丽亚·A.·海斯·派特南马可·君麦布勒斯尼克·克鲁德森安德鲁·贝克
Owner AMBRX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com